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Mitochondrial dysfunction and oxidative stress have been implicated in the etiology of Parkinson’s disease.
Therefore, pathways controlling mitochondrial activity rapidly emerge as potential therapeutic targets. Here,
we explore the neuronal response to prolonged overexpression of peroxisome proliferator-activated receptor
gamma coactivator-1 alpha (PGC-1a), a transcriptional regulator of mitochondrial function, both in vitro and in
vivo. In neuronal primary cultures from the ventral midbrain, PGC-1a induces mitochondrial biogenesis and
increases basal respiration. Over time, we observe an increasing proportion of the oxygen consumed by neu-
rons which are dedicated to adenosine triphosphate production. In parallel to enhanced oxidative phosphoryl-
ation, PGC-1a progressively leads to a decrease in mitochondrial polarization. In the adult rat nigrostriatal
system, adeno-associated virus (AAV)-mediated overexpression of PGC-1a induces the selective loss of dopa-
minergic markers and increases dopamine (DA) catabolism, leading to a reduction in striatal DA content. In add-
ition, PGC-1a prevents the labeling of nigral neurons following striatal injection of the fluorogold retrograde
tracer. When PGC-1a is expressed at higher levels following intranigral AAV injection, it leads to overt degen-
eration of dopaminergic neurons. Finally, PGC-1a overexpression does not prevent nigrostriatal degeneration
in pathologic conditions induced by a-synuclein overexpression. Overall, we find that lasting overexpression
of PGC-1a leads to major alterations in the metabolic activity of neuronal cells which dramatically impair
dopaminergic function in vivo. These results highlight the central role of PGC-1a in the function and survival
of dopaminergic neurons and the critical need for maintaining physiological levels of PGC-1a activity.
INTRODUCTION
Mitochondrial dysfunction is a crucial factor in the pathogen-
esis of neurodegenerative disorders affecting the aging brain
(1). In addition to energy supply, mitochondria integrate extra-
cellular signals and carry out essential cellular functions deter-
mining neuronal survival and death. Maintaining a pool of
healthy mitochondria and eliminating dysfunctional mitochon-
dria appear crucial for cellular homeostasis. Indeed, perturba-
tions in mitochondrial energy metabolism lead to reduced
adenosine triphosphate (ATP) levels, impaired calcium buffer-
ing and increased production of reactive oxygen species
(ROS) (2), potential contributors to neuronal degeneration.
In the broad array of environmental and genetic factors that
underlie the etiology of Parkinson’s disease (PD),
mitochondrial dysfunction emerges as a common denomin-
ator. PD-related toxins, such as 1-methyl-4-phenyl-1,2,3,6-
tetra-hydropyridine (MPTP) and rotenone, which provoke
selective degeneration of nigral dopaminergic neurons, both
inhibit the respiratory chain complex I (3). Furthermore,
some evidence for reduced complex I activity in PD brain
tissue highlights impairments in the electron transport chain
(ETC) as a possible cause of neurodegeneration.
The association of several genes with familial and sporadic
forms of PD has brought additional evidence regarding the
link between mitochondrial dysfunction and the pathogenic
process leading to PD (4). Alpha-synuclein (aSyn), parkin,
PTEN-induced putative kinase 1 (PINK1), DJ-1 and leucine-
rich repeat kinase 2 have been found to affect mitochondrial
function. In particular, PINK1 and parkin play critical roles
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in the quality control of mitochondria (5–7). The aSyn
protein, which is considered central to PD pathogenesis, can
directly interact with the mitochondria (8–10). Both cellular
and animal models demonstrate that aSyn can affect ETC
components and thereby lead to the excessive production of
ROS in dopaminergic neurons (8). Mutations or elevated
levels of aSyn accelerate the formation of protofibrils or oligo-
mers, which may form pores in biological membranes and in-
crease mitochondrial permeability in neurons (11).
Therefore, pathways controlling mitochondrial function
rapidly emerge as potential therapeutic targets. In this
context, the transcriptional coactivator peroxisome prolifer-
ator-activated receptor gamma (PPARg) coactivator-1 alpha
(PGC-1a) is considered a master regulator of mitochondrial
biogenesis and metabolism (12,13). In cooperation with
estrogen-related receptor alpha (ERRa), NRF1 and NRF2,
PGC-1a controls oxidative phosphorylation through expres-
sion of genes involved in the mitochondrial respiratory chain
(14,15). In parallel, PGC-1a promotes the expression of
enzymes important for the detoxification of ROS (16).
Recent publications have highlighted perturbations of
PGC-1a activity in neurodegenerative disorders, with a down-
regulation of PGC-1a or its major target genes in Huntington’s
disease (HD) (17,18), Alzheimer’s patients (19) and PD
(20,21). In addition, genetic variations in the PGC-1a gene
delay the onset of motor symptoms in HD by several years
(22). PGC-1a shows neuroprotective effects in a rodent
model of HD (18). Two recent studies demonstrate that
PGC-1a transgenic expression improves the survival and func-
tion of motor neurons in the SOD1G93A mouse model of amyo-
trophic lateral sclerosis (23,24). In this encouraging context,
PGC-1a has appeared as a promising therapeutic target in
PD, at the intersection between mitochondrial dysfunction
and resistance to oxidative stress.
Here, we have evaluated the effect of PGC-1a expression in
the dopaminergic system to assess how this regulator of mito-
chondrial function may control neuronal function and survival.
PGC-1a overexpression using recombinant adeno-associated
virus (rAAV) leads to profound alterations in neuronal meta-
bolic profile, consistent with changes in mitochondrial biogen-
esis, ATP production, mitochondrial polarization and
expression of genes implicated in mitochondrial function. In
the adult rat nigrostriatal system, PGC-1a induces dose-
dependent effects, ranging from a selective loss of dopamin-
ergic markers to overt degeneration of nigral neurons, consist-
ent with a reduction in striatal DA. These results demonstrate
that nigral dopaminergic are critically sensitive to the modifi-
cations in mitochondrial homeostasis induced by PGC-1a. To
explore the interaction between PGC-1a and pathological con-
ditions related to PD, we further investigate the effect of
PGC-1a in neurons expressing human aSyn.
RESULTS
PGC-1a induces mitochondrial biogenesis and increases
respiration rates in neurons from the ventral midbrain
In order to assess the effect of PGC-1a expression on the mito-
chondrial function of neuronal cells in vitro, we used primary
neuronal cultures derived from the mouse ventral midbrain.
These cultures were purely neuronal and contained a small
fraction of neurons expressing the dopaminergic markers tyro-
sine hydroxylase (TH) and DAT. Seven-day-old neuronal cul-
tures were infected with an identical dose of the AAV2/
6-PGC-1a or AAV2/6-GFP vectors. To fluorescently label
mitochondria, neurons were re-infected 3 days later with an
AAV2/6 vector encoding the red fluorescent protein fused to
a mitochondrial localization signal (MitoDsRed). Neurons
were analyzed 4 days later by flow cytometry (Fig. 1).
Neurons expressing PGC-1a and MitoDsRed showed a more
than 5-fold increase in the mean Cy5 fluorescence intensity
(306.9+ 93.0) when compared with the control groups
expressing GFP/MitoDsRed or MitoDsRed only (56.2+ 9
and 53.7+ 0.9, respectively), reflecting massive mitochon-
drial biogenesis in response to PGC-1a expression.
To further investigate the role of PGC-1a in cellular bio-
energetics, the oxygen consumption of cultured midbrain
neurons was measured using the XF-24 Analyzer (Fig. 2A–
D). Seven-day-old cultures were infected with AAV2/
6-PGC-1a or with a non-coding vector as control. Real-time
measurements of oxygen consumption rate (OCR) were
made at days 5 (Fig. 2A and B) and 7 post-infection
(Fig. 2C and D). At 5 days post-infection, neurons overexpres-
sing PGC-1a showed a clear increase in the basal OCR, which
remained significantly higher until day 7. To further decipher
the neuronal response to PGC-1a, we applied oligomycin to
inhibit ATP synthase activity, and FCCP, a mitochondrial pro-
tonophore uncoupling oxidative phosphorylation and dissipat-
ing the mitochondrial membrane potential. The difference
between untreated and oligomycin-treated cells defines the
OCR dedicated to ATP production. Following FCCP expos-
ure, the OCR reflects maximal respiration, and the difference
between this level and the basal rate represents the reserve res-
piration capacity. By measuring these parameters at 5 and 7
days post-infection, we observed a shift in the effect of
PGC-1a (Fig. 2B and D). Between day 5 and day 7, OCR cor-
responding to ATP production increased in response to
PGC-1a, and appeared significantly increased only at day 7.
Conversely, maximal respiration rate in the presence of
FCCP, which reflects the capacity of the cells to respond to
high ATP demand, was significantly increased at day 5 and
no more different at day 7. Similarly, the spared respiratory
capacity was significantly increased only at day 5.
Altogether, these data suggest that the increase in OCR at
the basal level initially reflects the increase in the mitochon-
drial mass coupled with oxidative phosphorylation. With
time in culture, neurons continue to consume more oxygen,
which is increasingly utilized for ATP production. However,
neuronal capacity to elevate its metabolic rate and accommo-
date rapid increases in metabolic demand is no more different
from control condition. Therefore, it appears that neurons tend
to maximize basal ATP production in response to PGC-1a.
PGC-1a induces changes in the expression of genes related
to mitochondrial function and polarization
To further investigate how PGC-1a could impact on mito-
chondrial function in mesencephalic neuronal cultures over
time, we measured changes in the expression of 84 mitochon-
drial genes. Seven-day-old midbrain cultures infected with
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either AAV2/6-PGC-1a or a non-coding vector were analyzed
at 5 (Fig. 3A) and 7 days (Fig. 3B) post-infection. The real-
time PCR array includes nuclear genes related to various mito-
chondrial functions, such as the intrinsic apoptotic pathway or
molecular transport across inner and outer membranes, which
controls the transfer of metabolites for the ETC and oxidative
phosphorylation as well as ions implicated in mitochondrial
membrane polarization. Several genes are also implicated in
mitochondrial fusion, fission and localization.
At 5 days post-infection (Fig. 3A), we observed several sig-
nificant changes in gene expression that may impact mitochon-
drial polarization. BCL2/adenovirus E1B interacting protein 3
(Bnip3) and ADP/ATP translocase (Slc25a4), two genes
that can promote proton leakage, were 3- and 1.5-fold
Figure 1. Mitochondrial biogenesis in neurons over-expressing PGC-1a. Primary neuronal culture from mouse ventral midbrain was cultured for 7 days and then
transduced with AAV2/6 encoding either PGC1 or GFP. Three days later, the neurons were infected with a vector encoding the MitoDsRed fluorescent protein
and analyzed by flow cytometry. Control conditions include non-infected (NI) neurons and neurons infected with the MitoDsRed (M) vector only. (A) Repre-
sentative flow cytometry dot plots: living cells were gated in region R1 of the FS/SS plot. Average Cy5 fluorescence intensity was determined for each group on
cells gated in region R2, identified as the population of neurons expressing the MitoDsRed fluorescent protein. (B) PGC1 neurons show a clear increase in
Cy5 fluorescence reflecting mitochondrial biogenesis. One-way ANOVA with Newman–Keuls post hoc test: NI, n ¼ 2; M, n ¼ 2; GFP, n ¼ 3; PGC1,
n ¼ 3; ∗P , 0.05.
Figure 2. Cellular respiration in neurons over-expressing PGC-1a. (A–D) Primary neuronal cultures were infected with either the NCV or the PGC1 vector at
day 7. Analysis of cellular respiration was performed at 5 (A) and 7 (C) days post-infection. OCRs were measured on 10 wells per group in basal conditions
during 60 min. In each group, a subset of four wells was then treated with 5 mM oligomycin (ATP synthase inhibitor) and OCR was measured during 60 min.
Finally, another subset of five wells per group was exposed to 20 mM FCCP (mitochondrial protonophore) and the OCR was measured during 30 min. (B and D)
Based on these measurements, we assessed the following OCRs: basal (n ¼ 10), dedicated to ATP production (n ¼ 4), in presence of FCCP (n ¼ 5) and reserve
capacity (n ¼ 5). Student’s t-test: ∗∗P , 0.01, ∗∗∗P, 0.001.
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up-regulated, respectively. We also measured a 1.6-fold down-
regulation of Bcl2, which maintains mitochondrial potential by
regulating proton flux (25).
PGC-1a also induced expression of genes implicated in
mitochondrial fusion, with a 1.3-fold up-regulation of both
mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2), and a significant
1.2-fold down-regulation of the mitochondrial fission
protein 1 (Fis1). At day 5, we further noticed an up-regulation
of most genes implicated in mitochondrial transport and local-
ization, such as the neurofilament light polypeptide (Nefl) and
MIRO-1 (Rhot1).
At 7 days post-infection (Fig. 3B), the number of genes with
significant changes in expression further increased. In particu-
lar, we noticed again a 2.5-fold up-regulation of the ADP/ATP
Figure 3. Mitochondrial transcriptome analysis of neuronal cultures overexpressing PGC-1a. Seven-day-old primary neuronal cultures from mouse ventral mid-
brain were infected with either a NCV or a vector encoding PGC-1a (PGC1). PCR arrays were performed at days 5 (A) and 7 (B) post-infection, to measure
changes in the expression of 84 nuclear genes involved in various mitochondrial functions. Dark grey columns indicate significant changes in gene expression
(n ¼ 4, Student’s t-test, P , 0.05). (C and D) To analyze mitochondrial membrane potential, neurons were incubated with the JC-1 sensor at 5 (C) and 8 (D)
days post-infection and the ratio green/red fluorescence measured. One-way ANOVA with Newman–Keuls post hoc test: NI, n ¼ 7; NCV, n ¼ 8; PGC1, n ¼ 7;
∗P , 0.05.
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translocase (Slc25a4). The Mfn1 and Opa1 genes involved in
mitochondrial fusion were also up-regulated. We measured an
important 4.1-fold up-regulation of the antioxidant gene Sod2
and an overall increase in the expression of transmembrane
solute carriers and proteins implicated in the transfer of pro-
teins across inner/outer mitochondrial membranes.
PGC-1a overexpression induces mitochondrial
depolarization
The observed metabolic response to PGC-1a and the pattern
of gene expression changes are indicative of potential effects
of PGC-1a on mitochondrial membrane potential in mesen-
cephalic neurons. Therefore, we further analyzed mitochon-
drial membrane potential using the JC-1 sensor at 5 and 8
days post-infection (Fig. 3C and D, respectively). When
JC-1 enters the mitochondria, it reversibly forms J-aggregates
and thereby produces red fluorescence as a function of the
mitochondrial membrane potential. Consequently, mitochon-
drial depolarization is indicated by a decrease in the red/
green fluorescence intensity ratio. At 5 days, no significant dif-
ferences were observed between groups. However, at 8 days
post-infection, ventral midbrain neurons expressing PGC-1a
showed a significant decrease in the red/green fluorescence in-
tensity ratio, when compared with neurons either non-infected
or infected with a non-coding control vector. This result indi-
cates that constant expression of PGC-1a indeed leads to sig-
nificant mitochondrial membrane depolarization in ventral
midbrain neurons. However, as we observed gene expression
and metabolic changes evolving over time in culture, it is im-
portant to determine their long-term effect in vivo. In addition,
primary cultures of ventral midbrain neurons contain mixed
populations of neurons with only a fraction of dopaminergic
neurons. Therefore, it is important to further address what
are the consequences of PGC-1a overexpression specifically
on the population of nigral dopaminergic neurons.
Recombinant AAV-mediated overexpression of PGC-1a
in the nigrostriatal system of adult rats
We sought to explore the effect of PGC-1a expression on
dopaminergic neurons in vivo, following unilateral injections
of AAV2/6 vectors. We used two modes of administration,
based on the ability of AAV2/6 vectors to transduce nigral
neurons either via direct injection at the level of the substantia
nigra pars compacta (SNpc) or by retrograde transport of the
vector from nerve terminals following intrastriatal injection.
These routes of administration differ by the pattern of trans-
duction obtained. Direct intranigral injection leads to robust
transgene expression mainly in the SNpc with a minimal
viral dose (5 × 106 TUs) (PGC1 Hi). The intrastriatal injection
of 6 × 107 TUs transduces striatal neurons as well as the
distant nigral neurons by retrograde transport of the viral par-
ticles along axonal projections. This mode of vector injection
leads to a lower level of transgene expression in nigral dopa-
minergic neurons when compared with direct intranigral injec-
tions, and will therefore be referred as ‘PGC1 Lo’. A similar
intrastriatal injection of an AAV2/6 vector expressing GFP
demonstrated retrograde transduction of 55.7+ 9.9% of the
nigral neurons expressing the dopaminergic marker TH.
Both modes of injection led to a robust expression of
PGC-1a at 3 months post-injection, as demonstrated by immu-
nostainings (Fig. 4A and B). To quantify the level of PGC-1a
mRNA expression induced, we performed a reverse transcrip-
tion-quantitative PCR (RT–qPCR) on striatal and SNpc
samples from PGC1 Hi and PGC1 Lo rats sacrificed at 3
weeks post-injection (Table 1). Following nigral injection,
we measured a 399.5+ 182.2-fold increase in the abundance
of the PGC-1a transcript in the SNpc, when compared with
the endogenous level in the non-injected control side. Expect-
edly, there was no difference in striatal PGC-1a expression. In
contrast, rats injected in the striatum showed a modest increase
in PGC-1a expression in the SNpc, with a 4.5+ 0.5-fold dif-
ference when compared with non-injected side. In the injected
striatum, the overall increase appeared of similar amplitude
(4.0+ 1.0-fold). However, striatal vector deposits result in
local expression of exogenous PGC-1a, which adds to the
high level of endogenous PGC-1a typically observed in striat-
al tissue (26). Therefore, one should consider the dilution
effect of measuring the localized expression of exogenous
PGC-1a as part of the large striatal structure.
Overexpression of PGC-1a induced mitochondrial biogen-
esis in the striatum of PGC1 Lo rats, as demonstrated by an
increase in the immunostaining for the mitochondrial marker
HSP60, a chaperonin for protein transport and folding in the
mitochondrial matrix (Fig. 4C).
PGC-1a induces perturbations in nigral dopaminergic
neurons, ranging from the loss of dopaminergic markers
to overt nigrostriatal degeneration
We next assessed the effect of PGC-1a expression on nigral
neurons and their striatal projections. In the group PGC1 Lo,
the expression of PGC-1a did not produce any significant loss
of neurons positive for the dopaminergic markers vesicular
monoamine transporter 2 (VMAT2) (Fig. 5A and E) and TH
(Fig. 5B), or any loss of Nissl-stained nuclei in the SNpc
(Fig. 5K) when compared with the control group non-coding
vector (NCV) Lo, injected in the striatum with a non-coding
vector. However, we noticed a decrease in staining intensity in-
dicative of marker down-regulation (Fig. 5E). Indeed, we
observed a reduction in VMAT2 (Fig. 5C and G), and TH immu-
noreactivity (Fig. 5D) at the level of the striatal nerve terminals
(35.2+2.6 and 37.3+2.5%, respectively). Interestingly, despite
the fact that the vector had been injected in the striatum, PGC-1a
did not produce any deleterious effect on striatal medium
spiny neurons, as demonstrated by the normal intensity of
the dopamine- and cyclic AMP-regulated phosphoprotein 32
(DARPP32) immunostaining (Fig. 5H). Therefore, PGC-1a
appears to selectively impact on the expression of dopaminergic
markers following intrastriatal vector injection.
In order to determine whether higher levels of PGC-1a may
lead to neuronal loss, we analyzed the animals directly
injected with the PGC-1a vector in the SNpc. At 3 months
post-injection, PGC1 Hi rats displayed an overt loss of
nigral neurons positive for VMAT2 (45.5+ 7.1%; Fig. 5A
and F) and TH (50.7+ 6.1%, Fig. 5B) when compared with
the group NCV Hi injected with a non-coding vector in the
SNpc. Dopaminergic innervation in the striatum was similarly
reduced. We measured a 63.0+ 7.1% loss for VMAT2
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(Fig. 5C and I) and a 60.9+ 7.5% loss for TH striatal immu-
noreactivity (Fig. 5D) when compared with the non-injected
hemisphere. Again, the expression of the DARPP32 marker
in striatal neurons remained intact (Fig. 5J).
Quantification of Nissl-stained neuronal nuclei in the SNpc
revealed a 24.3+ 4.2% reduction versus the non-injected side
(Fig. 5K). In parallel to the loss of dopaminergic markers, we
further explored if PGC-1a could induce any change in the ex-
pression of other neuronal markers. As PGC-1a has recently
been demonstrated to control parvalbumin (PV) expression
in interneurons (27), we immunostained striatal and ventral
midbrain sections for PV. Indeed, we found a clear
up-regulation of PV expression in the substantia nigra injected
with the PGC-1a vector, when compared with the non-
injected side or to the control group injected with a non-coding
vector in the SNpc (Fig. 6A and B), suggesting that the over-
expression of PGC-1a can perturb marker expression in sur-
viving neurons. We observed the same up-regulation of PV
expression in animals overexpressing PGC-1a in the striatum,
when compared with the non-injected side or the control group
injected with a non-coding vector (Fig. 6C and D). Interesting-
ly, the direct intrastriatal injection of the PGC-1a vector
appears to selectively change PV expression and not the
medium spiny neuronal marker DARPP32.
Altogether, these results highlight the effects of PGC-1a on
the expression of dopaminergic markers and neuronal survival
in the nigrostriatal system. Next, we sought to analyze how
PGC-1a impacts on neuronal functions, such as DA synthesis.
To determine these effects, we used only the cohort of rats
Figure 4. Overexpression of PGC-1a and long-term effects in vivo. (A) Nigral PGC-1a immunostaining at 3 months post-injection of an AAV2/6-PGC1 vector
directly in the rat SNpc. (B) Striatal PGC-1a immunostaining at 3 months post-injection of an AAV2/6-PGC1 vector in the rat striatum. (C) HSP60 immunos-
taining showing mitochondrial biogenesis in the striatum of a rat injected with an AAV2/6-PGC1 in the striatum. For each immunostaining, the non-injected side
(NInjS) is shown for comparison. Scale bar: 100 mm.
Table 1. Intranigral (PGC1 Hi, n ¼ 4) versus intrastriatal (PGC1 Lo, n ¼ 4)
injection of the AAV2/6-PGC1 vector: fold increase in the level of PGC-1a
mRNA expression in the substantia nigra and striatum of rats at 1 month post-
injection
Substantia nigra Striatum
Mean SEM Mean SEM
PGC1 Hi 399.5 182.2 0.4 0.3
PGC1 Lo 4.5 0.5 4.0 1.0
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with intrastriatal vector injections (PGC1 Lo), as these animals
display a moderate level of PGC-1a overexpression in the
SNpc with a minimal impact on neuronal survival.
PGC-1a overexpression impairs DA levels and DA
turnover in the striatum
The level of DA and its metabolites were determined in
extracts from striatal tissue. We compared rats injected in
the striatum with either the PGC-1a vector, leading to a
4.5-fold increase in the level of PGC-1a mRNA in the SNpc
(Table 1), or a control non-coding vector (AAV2/6-NCV),
both at a dose of 6 × 107 TUs. When compared with the non-
injected hemisphere, we measured a clear reduction in the stri-
atal DA level (42.9+ 1.7%) only in the PGC1 Lo group
(Fig. 7A), consistent with the loss in TH expression. The
levels of the DA metabolites DOPAC (74.6+ 3.3%) and
HVA (56.6+ 3.2%) appeared to be further reduced when
Figure 5. Loss of dopaminergic nigrostriatal markers in response to PGC-1a overexpression. (A and B) Loss of VMAT2-positive (A) and TH-positive (B)
neurons in the SNpc of rats displaying either a moderate (PGC1 Lo) or a high level of PGC-1a overexpression (PGC1 Hi) in the SNpc at 3 months post-injection.
Note the overt loss of VMAT2 and TH neurons in the PGC1 Hi condition. (C and D) Loss of striatal VMAT2 (C) and TH (D) immunoreactivity in PGC1 Lo and
PGC1 Hi rats at 3 months post-injection. Note in both conditions, the loss of striatal dopaminergic markers. (E and F) Representative photomicrographs showing
VMAT2-positive neurons in the SNpc of PGC1 Hi rats (E) and PGC1 Lo rats (F), when compared with the non-injected side (NInjS); scale bar: 100 mm. (G and
I) Representative photomicrographs showing the loss of VMAT2 marker in the striatum of PGC1 Hi (G) and PGC1 Lo rats (I). In both conditions, striatal
DARPP32 immunoreactivity remains intact (H and J—corresponding to PGC1 Hi and PGC1 Lo, respectively). (K) Stereological quantification of the percentage
loss of Nissl-positive neurons in the SNpc.
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compared with the non-injected hemisphere. In the control
group injected with a non-coding vector, the level of DA
and metabolites remained similar in both the injected and non-
injected striata.
We assessed DA turnover by calculating the ratio between
metabolites and total DA content: (DOPAC + HVA)/DA. In
response to PGC-1a, we observed a significant increase in
the relative abundance of DA metabolites (Fig. 7B). In the
striata injected with the AAV2/6-NCV vector, DA turnover
remained similar to the non-injected side. Increased DA turn-
over induced by PGC-1a could lead to increased production of
hydrogen peroxide associated with oxidative stress.
Consistent with the reduction in striatal DA observed at 3
months post-injection, PGC1 Lo animals showed a rotational
behavior induced by amphetamine, reaching 2.5+ 1.0 ipsiver-
sive turns per min, significantly increased from 0.5+ 0.6
Figure 6. PGC-1a up-regulates PV expression in the substantia nigra and striatum. Immunostaining demonstrating an increase in the amount of PV-positive
neurons in the injected SNpc and reticulata of rats injected with AAV2/6-PGC1 in the SNpc (A). No change in PV expression in rats injected with a non-coding
vector in the SNpc (B). PGC1 and NCV Hi; scale bar: 200 mm. A clear up-regulation of the striatal interneuron marker PV is found in rats injected with AAV2/
6-PGC1 in the striatum (C), in contrast to rats similarly injected with a non-coding vector (D). PGC1 and NCV Lo; scale bar: 250 mm.
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contraversive turns per min before vector injection (P, 0.01,
paired t-test). The same animals displayed neither any
apomorphine-induced rotations, nor any spontaneous asym-
metry in forepaw use.
As suggested by the observed loss of dopaminergic markers
in the striatum, PGC-1a induced a clear decrease in DA levels,
in part due to an increase in the turnover rate.
In response to PGC-1a, nigral neurons show a clear defect
in retrograde labeling following striatal injection of the
fluorogold tracer
As the loss of dopaminergic markers appeared most evident in
striatal fibers following intrastriatal injection of the PGC-1a
vector (PGC1 Lo), we further explored nigrostriatal axonal
transport in these conditions. Three months post-injection of
the vector, animals were injected in the striatum with the
neuroanatomical retrograde tracer fluorogold and sacrificed 5
days later. As expected, we observed a fluorogold signal in
the majority of the nigral neurons in the animals injected
with the control vector AAV2/6-NCV, demonstrating an
intact capacity to retrogradely transport the tracer (Fig. 8).
In stark contrast, no fluorogold signal could be detected in
TH-positive neurons on the hemisphere injected with 6 ×
107 TUs of the AAV2/6-PGC-1a vector. Considering the sig-
nificant proportion of neuronal cell bodies and striatal axonal
fibers that are still present in these conditions, this result
denotes impaired synaptic uptake or disruption of the axonal
retrograde transport in response to PGC-1a.
Altogether, these results demonstrate that the level of
PGC-1a impacts on the mitochondrial function of neurons
from the ventral midbrain and thereby affects nigrostriatal
function in normal adult animals. Next, we sought to explore
the effect of PGC-1a overexpression in pathologic conditions
related to PD. The expression of human aSyn using AAV
vectors was used to specifically induce pathological changes
in the rat nigrostriatal system.
Nigrostriatal PGC-1a overexpression does not prevent the
degeneration of nigral dopaminergic neurons expressing
human aSyn
We have previously reported that the expression of human
aSyn in the rat SNpc using AAV2/6 vectors leads to mild neu-
rodegeneration (28). In order to assess the effect of PGC-1a on
aSyn pathology, adult rats were injected in the SNpc with
AAV2/6 encoding either human wild-type aSyn (aSynWT)
or the PD-associated mutant A53T, at a dose of 2 × 107
TUs. These conditions induce progressive nigrostriatal neuro-
degeneration associated with moderate behavioral impair-
ments (M. Gaugler et al., manuscript in preparation). In the
same time, the animals were injected in the ipsilateral striatum
with the AAV2/6-PGC-1a vector to induce a moderate expres-
sion of PGC-1a in the SNpc. Control rats received a similar
injection of the non-coding vector.
The activity of both forepaws was monitored in the cylinder
test, where the animals showed a reduction in the use of the
left forepaw in response to aSyn expression (Fig. 9A and
B). Overall, we did not observe any significant changes in
spontaneous motor activity in response to PGC-1a. Although
the animals injected with the PGC-1a displayed a non-
significant trend towards improved motor symmetry at 1
month for aSynWT, and until 2 months for the A53T
mutant, motor activity of the left forepaw then deteriorated
and reached the same level as control animals expressing
aSyn only.
However, we noticed a significant difference in
amphetamine-induced rotations (Fig. 9C). Indeed, when com-
pared with the animals expressing only aSyn, the rats
co-injected with the PGC-1a vector showed ipsiversive behav-
ior, which likely reflects the reduction in striatal DA due to
PGC-1a. Overall, the amphetamine-induced rotational
response to both aSyn and PGC-1a remained weak.
At 3 months post-injection, we analyzed the effect of
PGC-1a on nigral dopaminergic neurons expressing human
aSyn. PGC-1a did not prevent the loss of VMAT2-positive
nigral neurons induced by expression of either the wild-type
or A53T forms of aSyn. In animals expressing the A53T
mutant, the cell loss appeared similar with both PGC-1a and
the non-coding vector (Fig. 9D). In the aSynWT condition,
there was a trend towards increased loss of VMAT2-positive
Figure 7. Depletion of DA and metabolites and increased DA turnover. (A)
Total striatal content of DA, DOPAC and HVA in the non-injected and
injected hemispheres of PGC1 Lo and NCV Lo rats at 3 months post-injection.
Results are expressed as the ratio of metabolite concentration in the injected
versus non-injected hemisphere. Note the significant decrease in striatal
levels of DA and metabolites in PGC1 Lo rats. Student’s t-test: NCV Lo:
n ¼ 2, PGC1 Lo: n ¼ 5; ∗P, 0.05, ∗∗∗P, 0.001. (B) PGC1 Lo rats show
higher DA turnover. DA turnover is determined as ([DOPAC]+[HVA])/
[DA]. Student’s t-test: NCV Lo, n ¼ 2; PGC1 Lo, n ¼ 5, ∗∗P , 0.01.
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neurons with the PGC-1a vector, versus the non-injected side
(aSynWT + PGC1: 29.3+ 4.7%, aSynWT + NCV: 18.9+
3.2%). However, the difference did not reach statistical signifi-
cance (P ¼ 0.14; Fig. 9D).
In the striatum, we again observed a significant increase in
the loss of VMAT2 immunoreactivity in conditions of
PGC-1a overexpression (Fig. 9E). The effect was similar
when PGC-1a was combined with either aSynWT
(aSynWT + PGC1: 39.6+ 3.6%, versus aSynWT + NCV:
15.9+ 4.9%) or the A53T mutant (A53T + PGC1: 43.0+
5.1%, versus A53T + NCV: 15.3+ 7.2%).
Overall, moderate levels of PGC-1a overexpression in
normal rats lead to cellular and mitochondrial changes
which selectively interfere with the dopaminergic phenotype
of nigral neurons. In pathologic conditions induced by
human aSyn, PGC-1a overexpression does not oppose neuro-
degeneration.
DISCUSSION
Although PGC-1a is considered a promising target for neuro-
degenerative disease associated with mitochondrial dysfunc-
tion, few studies have assessed the effect of PGC-1a
overexpression in the central nervous system. In a mouse
model for amyotrophic lateral sclerosis, transgenic expression
of PGC-1a has protective effects against mutated SOD1
toxicity (23,24). Here, we overexpress PGC-1a in the
nigrostriatal system using an AAV vector which primarily
targets striatal neurons, and retrogradely infects nigral
dopaminergic neurons. We find that PGC-1a expression in
the SNpc selectively impacts on the dopaminergic function,
leading to reduced expression of dopaminergic markers,
increased DA turnover, impaired retrograde axonal transport
and neuronal loss.
In primary cultures derived from the ventral midbrain,
PGC-1a affects mitochondrial function in a time-dependent
manner. PGC-1a induces mitochondrial biogenesis, consistent
with increased oxidative phosphorylation reflected by an
augmentation in oxygen consumption. However, neuronal
metabolic activity changes over time in response to PGC-1a.
Indeed, although the basal cell respiration rate remains
higher than control, less oxygen is used for ATP production.
Mitochondria display a significant reduction in their reserve
respiratory capacity and a significant decrease in membrane
potential. The uncoupling of oxidative phosphorylation dedi-
cated to ATP production that progressively appears in re-
sponse to PGC-1a could be seen as an adaptive mechanism
to lessen the production of ROS. As mitochondrial metabolism
is recognized as the most important source of ROS (29), mito-
chondrial biogenesis is expected to increase oxidative stress in
neurons. Therefore, the progressive alteration of the mitochon-
drial function may limit ROS production despite the observed
increase in the mitochondrial mass.
Here, we find that the neuronal response to PGC-1a is asso-
ciated with the clear up-regulation of several genes implicated
in the loss of mitochondrial membrane potential and oxidative
stress resistance (Slc25a4, UCP3, Bnip3, Sod2). In particular,
Slc25a4, also known as ADP/ATP translocase 1 (ANT1), is a
major mitochondrial constituent and a core component of the
mitochondrial permeability transition pore. ANT1 is respon-
sible for the transfer of ADP and ATP through the inner mito-
chondrial membrane, a process highly dependent on the proton
gradient. ANT1 overexpression has been reported to induce
rapid cell death with a concomitant decrease in mitochondrial
membrane potential (30,31). UCP3, which is activated by
superoxide, increases mitochondrial proton conductance and
dissipates the membrane gradient (32,33). Bnip3 is a
pro-apoptotic protein, member of the Bcl-2 family. Upon acti-
vation, Bnip3 inserts into the mitochondrial outer membrane,
which causes opening of the mitochondrial permeability tran-
sition pore, loss of mitochondrial potential, generation of ROS
and necrosis (34). Sod2, a manganese-binding protein in the
mitochondrial matrix, is critically involved in superoxide de-
toxification (35). The up-regulation of Sod2 may contribute
to neuronal survival in conditions of increased ROS
production. Overall, the pattern of gene expression changes
Figure 8. Absence of fluorogold retrograde labeling in nigral dopaminergic neurons overexpressing PGC-1a. Immunostaining for TH expression and fluorogold
uptake at 3 months post-injection of either PGC-1a or non-coding vector. Note the absence of fluorogold signal in the SNpc of PGC1 Lo rats, indicative of
impaired uptake or retrograde transport of the tracer. PGC1 and NCV Lo; scale bar: 100 mm.
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suggests a cellular response to oxidative stress, coherent
with the observed increase in the basal rate of oxidative
phosphorylation.
There is converging evidence for alterations of axonal traf-
ficking in response to PGC-1a overexpression in midbrain
dopaminergic neurons. Striatal fluorogold injections reveal a
complete absence of tracer labeling in nigral cell bodies, dem-
onstrating either impaired synaptic uptake or reduced retro-
grade transport of the tracer. In addition, we observed
consistent changes in the expression of several genes related
to axonal transport and mitochondrial movement along
axons, such as up-regulation of the Nefl and Rhot1. Nefl is
implicated in the localization of mitochondria, which
depends on the docking of mitochondria to microtubules and
neurofilaments (36). As the direction of mitochondrial trans-
port along axons also depends on organelle membrane poten-
tial (37), it is possible that the expression of PGC-1a produces
major perturbations in organelle trafficking, which may ultim-
ately cause axonal degeneration and cell death.
In rats injected with the AAV-PGC-1a vector, we find that
PGC-1a overexpression opposes nigral dopaminergic
function. The effect is progressive, as demonstrated by the
slow development of amphetamine-induced rotational
behavior, and primarily affects nigrostriatal axonal projec-
tions. As part of the mechanisms opposing dopaminergic func-
tion in response to PGC-1a, we observed an increase in DA
turnover. The expression of monoamine oxidase B present
on the mitochondrial outer membrane is regulated by
Figure 9. Loss of dopaminergic markers and behavioral assessment in response to PGC-1a overexpression in rats expressing human aSyn. Rats were injected in
the SNpc with AAV2/6 vectors encoding either human aSynWT or the A53T mutant. The animals were simultaneously injected in the striatum with an AAV2/6
vector encoding PGC-1a or a NCV to ensure a moderate expression in the SNpc. (A–C) To assess motor asymmetry, forepaw activity was measured in the
cylinder test (A and B) and ipsiversive rotations were measured following amphetamine administration (C). In the cylinder test, note the progressive development
of an asymmetry in forepaw use typically observed following unilateral expression of aSynWT or A53T (repeated measure ANOVA, time effect: P , 0.005).
PGC-1a does not significantly rescue the behavioral phenotype induced by aSyn in the cylinder test. In amphetamine-induced rotational behavior, PGC-1a
induces a significant change towards ipsiversive rotations (one-way ANOVA with Newman–Keuls post hoc test; n ¼ 10 in each group: ∗P , 0.05, ∗∗P ,
0.01 and ∗∗∗P , 0.001). (D and E) PGC-1a overexpression does not protect against aSyn toxicity, as demonstrated by the loss of nigral VMAT2-positive
neurons (D) and striatal VMAT2-positive fibers (E); n ¼ 10 animals per group. Student’s t-test, ∗∗P , 0.01.
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PGC-1a and ERRa (38). DA enzymatic catabolism by mono-
amine oxidase produces hydrogen peroxide causing oxidative
stress and protein oxidation (39). Increased DA oxidation may
therefore contribute to the selective demise of nigral neurons.
The effect of PGC-1a on the survival of nigral dopaminergic
neurons appears to highly depend on its level of overexpres-
sion. While striatal injections of the PGC-1a vector lead to
the down-regulation of dopaminergic markers, intranigral
vector injections cause overt neuronal loss. Furthermore, we
find that injections of the PGC-1a vector upregulates PV, a
marker for GABAergic interneurons. It has already been
reported that PGC-1a can induce PV expression in neuroblast-
oma cells (27). In the brain, PGC-1a, PV and mitochondria
coordinately regulate Ca2+ homeostasis in a cell-specific
manner. Interestingly, mice ectopically expressing PV in
neurons show alterations in Ca2+ homeostasis and a reduced
mitochondrial volume (40).
Interestingly, PGC-1a expression in the striatum does not
affect GABAergic medium spiny neurons, highlighting the
selective vulnerability of dopaminergic neurons to the
changes induced by PGC-1a. Therefore, DA could represent
an important mediator in potentiating PGC-1a toxicity in the
nigrostriatal system. The loss of striatal dopaminergic
markers and nigral degeneration are most likely due to mito-
chondrial dysfunction. Mitochondria are crucial organelles
for the energy-demanding process of synaptic neurotransmis-
sion. The distribution and trafficking of mitochondria affect
neurotransmitter synthesis, release and recycling
through energy metabolism and synaptic calcium modulation
(41–43). Synaptic mitochondria are more sensitive to a de-
crease in oxidative phosphorylation (44). The cellular morph-
ology of nigral dopaminergic neurons, with long and highly
branched striatal neurites, as well their exposure to calcium
signaling (45) may therefore contribute to the observed
impact of PGC-1a.
Altogether, this study emphasizes the importance of tightly
controlling the expression of PGC-1a in dopaminergic
neurons. PGC-1a is a powerful regulator of energy metabol-
ism and its overexpression has already proved similarly detri-
mental in muscle and heart tissues. Cardiac PGC-1a
overexpression causes severe abnormalities in the myocyte
architecture due to extensive mitochondrial proliferation
(46,47). In the skeletal muscle, PGC-1a overexpression
enhances not only mitochondrial biogenesis but also respir-
ation uncoupling, leading to muscle atrophy (48). However,
PGC-1a expression within physiological limits does indeed
improve insulin sensitivity both in normal and insulin-resistant
skeletal muscle (49).
In the present study, we show that the function and survival
of nigral dopaminergic neurons are selectively vulnerable to
the progressive metabolic changes caused by the overexpres-
sion of PGC-1a, to levels beyond those observed under
normal physiological circumstances. In the context of PD,
mounting evidence highlights the critical links that exist
between the pathologic process and PGC-1a activity (20,21).
Notably, the E3 ubiquitin ligase parkin has recently been
found to control the level of PARIS, a transcriptional repressor
of PGC-1a (50). Pioglitazone, an agonist of PPARg which has
been shown to induce PGC-1a activity, is neuroprotective in
the MPTP model of PD (51–53). Based on these effects and
on the increasing evidence for the critical role of PGC-1a in
the pathology, a phase II clinical trial has been launched in
PD patients to assess the effects of pioglitazone on the early
phase of the disease. It will be of interest to determine the
effects of this compound in the disease context where a pre-
existing down-regulation of PGC-1a has to be expected.
However, it should be noted that Breidert et al. (51) also
found a significant reduction in striatal DA in pioglitazone-
treated mice prior to MPTP intoxication, further amplifying
the notion that up-regulating PGC-1a in normal animals
may impact on the dopaminergic function.
Although PGC-1a expression should be carefully con-
trolled, our data confirm the crucial role of this transcriptional
co-activator in the function and survival of dopaminergic
neurons. In PD, it appears therefore critical to design thera-
peutic strategies maintaining a tight and physiological regula-
tion of PGC-1a expression in the nigrostriatal system.
MATERIALS AND METHODS
Plasmid construction
Human WT (nucleotides 46–520, GeneBank accession no.
NM_000345) and A53T aSyn and mouse PGC-1a (nucleo-
tides 35–2428, GeneBank accession no. BC066868) were
inserted into the pAAV-pgk-MCS backbone, modified from
the serotype 2 pAAV-cmv-MCS (Agilent, La Jolla, CA,
USA) using standard cloning procedures.
Recombinant AAV2/6 production and titration
Recombinant pseudotyped rAAV2/6 were produced, purified
and titrated as described previously (54). A stuffer sequence
was included in the plasmid pAAV-pgk-MCS to generate a
non-coding vector with a comparable genome size. Vector
titration has been determined as described previously (54).
The measured titers were as follows: AAV-pgk-aSynWT
9.0 × 1010 TU/ml; AAV-pgk-A53T 5.0 × 1010 TU/ml; AAV-
pgk-MCS (non-coding vector) 4.5 × 1010 TU/ml; AAV-pgk-
PGC-1a 8.7 × 1010 TU/ml; 7.4 × 1010 TU/ml; AAV-
cmv-GFP 1.5 × 1010 TU/ml and AAV-cmv-MitoDsRed
8.9 × 109 TU/ml.
Stereotaxic unilateral injection into the SNpc and striatum
of rats
Female adult Sprague-Dawley (Charles River Laboratories,
France), weighing 200 g were housed in a 12 h light/dark
cycle, with ad libitum access to food and water, in accordance
with Swiss legislation and the European Community Council
directive (86/609/EEC) for the care and use of laboratory
animals. AAV vectors were injected unilaterally in the right
hemisphere. Stereotaxic injections into the SNpc were
performed as described previously (54). In the striatum,
virus suspension was injected in two deposits along three
needle tracts at the following coordinates: anterior–posterior
(AP)/mediolateral (ML) relative to bregma/dorsoventral
(DV) relative to skull surface 1.7 mm/22.8 mm/25.8 mm
and 24.2 mm, +0.7 mm/23.2 mm/26.3 mm and 25 mm,
20.4 mm/23.8 mm/26.2 mm and 25 mm. Two microliters
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of rAAVs at a concentration of 5 × 109 TU/ml were injected
per site using a 10 ml Hamilton syringe with a 34-gauge
blunt tip needle at a speed of 0.2 ml/min, with an automatic
pump (CMA Microdialysis, Sweden). The more ventral site
in each needle tract was injected first and the needle was
left in place for 2 min before slowly moving to the more
dorsal site. After injection, the needle was left for an addition-
al 5 min before slowly being withdrawn. To study the retro-
grade transport, a fluorogold preparation was injected at one
site in the striatum 5 days before sacrifice. The striatum was
targeted at the following coordinates: AP +0.2, ML 23,
DV +5. The concentration of the fluorogold was at 2% in
normal sterile 0.9% saline.
Primary neuronal culture from mouse ventral midbrain
The protocol used for the preparation of the primary neuron-
al culture from mouse ventral midbrain was adapted from
reference (55). The ventral midbrain portion of embryonic
brains (E16) was dissected out under a microscope and
kept in warm Hank’s buffered salt solution (HBSS) wo
Ca2+ and Mg2+. Mesencephalic tissues were isolated and
dissociated with gentle mechanical trituration, followed by
an enzymatic digestion in Trypsin/ethylenediaminetetraacetic
acid diluted in warm HBSS w/o Ca2+ and Mg2+ (1:1) for
20 min at 378C. Enzyme inactivation is done by adding
the Neurobasal medium supplemented with 10% heat inacti-
vated fetal bovine serum, GlutaMAX 1× and 1% Pen-Strep
(dissociation medium). Dissociated cells were centrifuged
5 min at 800 rpm and resuspended in the dissociation
medium. Cells were, then, filtered (40 mm) and centrifuged
5 min at 800 rpm. Neurons were, finally, resuspended in
the plating medium: neurobasal medium low glucose supple-
mented with B27 1×, GlutaMAX 1×, 20 mM pyruvate and
1% Pen-Strep. The cell concentration and the viability were
determined using a classic dye exclusion method (Trypan
Blue). Neurons were seeded into 24-well culture plates pre-
coated with poly-D-lysine (100 mg/ml) and laminin (20 mg/
ml) at 7.5 × 104 cells per well. Plates were maintained at
378C in a humidified atmosphere of 5% CO2. Seven-day-old
cultures were used for AAV infections. For AAV-mediated
transduction, each 24-well was infected with a viral dose
of 6 × 106 TUs.
Flow cytometry
Primary midbrain neurons were seeded in precoated 24-well
plates at 1 × 105 cells per well and cultured for 7 days in
378C/5% CO2 incubators. Neurons were then infected with
an AAV2/6 coding for PGC-1a or GFP at a dose of 6 × 106
TUs. Three days later, neurons were infected with a vector en-
coding the MitoDsRed fluorescent protein at a dose of 6 × 106
TUs. Two days later, cultures were harvested and neurons
were carefully collected with a cell scraper. Neurons were
fixed using 4% paraformaldehyde for 15 min at RT. After
two washes in 1× phosphate buffered saline, cell PE-Cy5
fluorescence was measured using a flow cytometer (CyAn
ADPS analyzer, Beckman Coulter).
Measurements of oxygen consumption
Oxygen measurements were made using the XF24 Extracellu-
lar Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA).
Primary midbrain neurons were seeded in pre-coated
XF24-well microplates at 7.5 × 104 cells per well and cultured
for 7 days in 378C/5% CO2 incubators. Neurons were then
infected with an AAV2/6 coding for PGC-1a or a non-coding
vector at a dose of 6 × 106 TUs. The basal respiration rate was
measured during 60 min. Assay protocols including compound
injection are preprogrammed through an excel template. Com-
pounds of interest (Oligomycin and FCCP) were loaded in the
drug delivery system of sensor cartridge before calibration.
The assay cartridge was first placed into XF Analyzer to
allow automatic calibration of optical sensors. Then, the cell
culture plate was inserted into the instrument. Basal OCRs
were measured six times before drug addition. Drugs that
have been preloaded into the drug delivery chambers of the
assay cartridge were then pneumatically injected, sequentially,
into the media in each well. After mixing, post-exposure OCR
measurements were made three times. The effects on cellular
respiration rates were measured during 60 min after addition
of oligomycin and during 30 min after addition of FCCP.
Measurements of mitochondrial depolarization
Studies of mitochondrial depolarization have been made with
MitoProbeTM JC-1 Assay Kit (Invitrogen). Primary midbrain
neurons were seeded in precoated 24-well plates at 1 × 105
cells per well and cultured for 7 days in 378C/5% CO2 incuba-
tors. Neurons were then infected with an AAV2/6 coding for
PGC-1a or a non-coding vector at a dose of 6 × 106 TUs.
Neurons were incubated 20 min with 2 mM JC-1, and then
washed twice with warm Neurobasal medium without
phenol red. Plates were analyzed on a fluorometer (Tecan
Safire2 microplate reader) using wavelengths at 497 nm for
excitation and 527 nm (green fluorescence) and 597 nm (red
fluorescence) for emission.
RNA extraction and RT–QPCR
In vitro studies. Primary midbrain neurons were seeded in pre-
coated 24-well plates at 1 × 105 cells per well and cultured for
7 days in 378C/5% CO2 incubators. Neurons were then
infected with an AAV2/6 coding for PGC-1a or a non-coding
vector at a dose of 6 × 106 TUs. Five and 7 days post-
infection, cultures were harvested and neurons were collected
with a cell scraper. Total RNA was isolated with RNAeasy
Mini Kit (Qiagen Inc., Valencia, CA, USA). cDNA was pre-
pared using RT2 First Strand Kit (SA Biosciences, Frederick,
MD, USA). The expression levels of 84 mitochondrial genes
implicated in biogenesis and function and 12 housekeeping
genes including internal controls were measured by quantita-
tive RT–PCR using RT2 ProfilerTM PCR Array (SA Bios-
ciences). Assays were run on a ABI 7900HT 384-Well
Block (Applied Biosystems, Foster City, CA, USA) using
the following cycling conditions (10 min at 958C, then 15 s
at 958C and 1 min at 608C for 40 cycles). Four independent
pairwise comparisons (PGC1 versus NCV) were performed
at two time points to evaluate scored differences in gene
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changes. An integrated web-based software package for the
PCR Array System was used to perform DDCt-based fold
change calculations from the uploaded raw threshold cycle
data.
In vivo studies. To determine the level of PGC-1a mRNA
expression in the SN and the striatum, rats were killed by de-
capitation at 3 weeks after rAAV injection (n ¼ 4 per group).
Striata and SN were rapidly dissected. Total RNA was isolated
with an RNAeasy Mini Kit (Qiagen). cDNA was prepared
using a Omniscript Reverse Transcription Kit. Briefly, total
RNA (50 ng) was reverse transcribed in a final volume of
20 ml with OligodT primers at 378C for 1 h according to the
manufacturer’s instructions. The expression level of PGC-1a
was measured by RT–QPCR using SybrGreen assays. The
genes ACTB and B2M were used as endogenous controls.
We used Quantitect Primer Assays (Qiagen) to quantify ex-
pression of these three genes. Each assay was run in duplicate,
with the Rotor-Gene Sybr Green PCR Kit (Qiagen) on a
Rotor-Gene Cycler using the following cycling conditions:
5 min at 958C, then 5 s at 958C and 10 s at 608C for 40 cycles.
Each replicate cycle threshold (Ct) was normalized to the
average Ct of the two endogenous controls on a per sample
basis. The comparative Ct method was used to calculate relative
levels of PGC-1a expression, as described previously (56,57).
Immunohistological analyses and quantification of
nigrostriatal lesions
Rats were sacrificed and tissue processed as described before
(28,54). Primary antibodies used in this study were anti-TH
(Rabbit IgG, 1:1000; AB152, Chemicon), anti-VMAT2
(rabbit IgG, 1:2000; AB1767, Chemicon), anti-DA and cyclic
AMP-regulated phosphoprotein, relative molecular mass
32000 (DARPP32) (Rabbit IgG, 1:1000; AB1656, Chemicon),
anti-PV (rabbit IgG, 1:6000; PV-28 Swant, Bellinzona, Switzer-
land), anti-PGC-1a (rabbit IgG, 1:1000; generous gift from Dan
Kelly, Burnham Institute for Medical Research, Orlando, FL,
USA) and anti-heat shock protein 60 kDa (HSP60) (mouse
IgG, 1:250; LK-1, Calbiochem). For fluorescence labeling, we
used secondary antibodies conjugated to Alexa Fluor-488
(1:500; Invitrogen), Cy3 (1:1000; Jackson ImmunoResearch).
For bright-field microscopy, we used biotinylated goat anti-
rabbit secondary antibody (1:200; Vector Laboratories). Stereo-
logical estimates of Nissl-positive and TH-positive nigral
neurons were made as described previously (58). For quantifica-
tion of VMAT2-positive neurons, the percentage of neuronal
loss was determined in a blinded fashion by counting nigral
dopaminergic neurons using bright-field microscopy, as
described previously (28,54). Of note, stereological estimates
and neuron counting on the same groups of samples yielded
identical results. The extent of striatal dopaminergic innervation
was measured by determining the optical density on immunos-
tained slices (54).
HPLC analysis of DA and DA metabolites
Contents of DA and DA metabolites were measured as
described before (54). Results are expressed as a percentage
of the non-injected hemisphere.
Behavioral analysis
Cylinder test and amphetamine-induced rotation test were per-
formed as described previously (54), before virus injection and
at monthly intervals post-surgery. In the cylinder test, only the
measurements with a minimum of 20 touches were included in
the analysis.
Statistical analysis
Data are expressed as average+ standard error of the mean
(SEM). Statistical analysis was performed using the Statistica
software (StatSoft Inc., OK, USA). Level of significance was
set at 0.05. Applied statistical tests are indicated in the figure
legends.
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